Table 2.

Ratio of pharmacokinetic parameters for each age group versus the youngest age group (≥ 20 to  < 25 years) for a single dose of 20 mg teneligliptin in the virtual Japanese and European descent populations

Age group (years)	Single dose
	Japanese			European descent
	AUC0–∞	Cmax	t½	AUC0–∞	Cmax	t½
≥ 20 to  < 25 (reference)	1.00	1.00	1.00	1.00	1.00	1.00
≥ 25 to  < 30	1.01	1.02	0.98	0.94	1.02	1.04
≥ 30 to  < 35	1.03	1.02	1.03	0.98	1.04	1.02
≥ 35 to  < 40	1.00	0.93	1.03	1.02	0.96	1.07
≥ 40 to  < 45	1.06	0.97	1.09	1.07	0.97	1.08
≥ 45 to  < 50	1.08	1.01	1.06	1.08	1.03	1.16
≥ 50 to  < 55	1.15	0.99	1.18	1.18	1.07	1.18
≥ 55 to  < 60	1.16	0.94	1.16	1.27	0.99	1.27
≥ 60 to  < 65	1.31	1.00	1.29	1.36	1.00	1.31
≥ 65 to  < 70a	1.35	1.04	1.27	1.30	0.95	1.39
≥ 70 to  < 75	N.A.	N.A.	N.A.	1.77	1.15	1.58
≥ 75 to  < 80	N.A.	N.A.	N.A.	1.80	0.97	1.73
≥ 80 to  < 85	N.A.	N.A.	N.A.	2.04	1.12	1.82
≥ 85 to  < 90	N.A.	N.A.	N.A.	2.07	1.09	1.89
≥ 90 to  < 94	N.A.	N.A.	N.A.	2.28	1.16	2.04
≥ 94 to  ≤ 98	N.A.	N.A.	N.A.	2.17	1.12	1.97

AUC_0–∞ Area under the plasma concentration–time curve from 0 h to infinity, C_max maximum plasma concentration, N.A. not available, t_½ elimination half-life

^a≥ 65 to  ≤  70 in Japanese subjects